Enhabit (NYSE:EHAB) Updates FY 2025 Earnings Guidance

Enhabit (NYSE:EHAB) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 0.410-0.510 for the period, compared to the consensus EPS estimate of 0.290. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Jefferies Financial Group upgraded shares of Enhabit from a “hold” rating to a “buy” rating and increased their price objective for the company from $8.25 to $9.50 in a report on Monday, December 9th. Leerink Partners reaffirmed a “market perform” rating and issued a $8.00 price target (down previously from $8.50) on shares of Enhabit in a report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, Enhabit presently has an average rating of “Hold” and an average price target of $8.75.

Enhabit Trading Up 1.0 %

Shares of NYSE:EHAB traded up $0.08 during mid-day trading on Wednesday, hitting $8.55. The stock had a trading volume of 306,020 shares, compared to its average volume of 276,512. Enhabit has a 12-month low of $6.85 and a 12-month high of $11.74. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.46 and a current ratio of 1.46. The company has a market cap of $430.13 million, a PE ratio of -3.69 and a beta of 1.83. The company’s 50 day moving average is $8.16 and its 200-day moving average is $7.90.

Enhabit (NYSE:EHAB) last issued its earnings results on Wednesday, March 5th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.03). Enhabit had a positive return on equity of 1.67% and a negative net margin of 11.24%. On average, sell-side analysts predict that Enhabit will post 0.22 EPS for the current year.

Insider Buying and Selling at Enhabit

In related news, Director Stuart M. Mcguigan bought 15,000 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was bought at an average price of $8.81 per share, with a total value of $132,150.00. Following the purchase, the director now directly owns 46,810 shares of the company’s stock, valued at approximately $412,396.10. This represents a 47.15 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey Bolton purchased 4,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $8.69 per share, for a total transaction of $34,760.00. Following the completion of the purchase, the director now directly owns 98,144 shares of the company’s stock, valued at $852,871.36. The trade was a 4.25 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.90% of the company’s stock.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.